HSCT-TMA: Mechanisms, Diagnosis, and Clinical Challenges

HSCT-TMA, or transplant-associated thrombotic microangiopathy, is a serious complication of hematopoietic stem cell transplantation in which widespread damage to the inner lining of small blood vessels triggers uncontrolled clotting, organ injury, and a sharply higher risk of death. The condition is driven largely by runaway activation of a branch of the immune system called the complement pathway, and it remains one of the most difficult post-transplant complications to diagnose and treat. Depending on which diagnostic criteria are applied, it may affect anywhere from roughly one in eight to nearly one in three transplant recipients within the first hundred days, and definite cases carry a mortality hazard more than five times higher than in patients without TMA.

How Endothelial Injury Gets the Process Started

The cells lining the inside of blood vessels, called endothelial cells, take a beating during a stem cell transplant. Chemotherapy and radiation used in the conditioning regimen damage them directly. Then the transplant itself layers on additional insults: pro-inflammatory molecules released during the procedure, bacterial toxins that leak through a gut lining weakened by conditioning, and the inflammatory surge that accompanies engraftment of the new donor cells all compound the injury.¹ Calcineurin inhibitors such as cyclosporine and tacrolimus, which are given to prevent graft-versus-host disease, add yet another source of endothelial stress. The result is a vascular lining primed for trouble well before any overt signs of TMA appear.

Under normal circumstances, healthy endothelial cells keep complement activation in check and prevent clots from forming inside blood vessels. Once those cells are injured, they lose that protective function. Complement proteins, which normally help the immune system clear pathogens, begin attacking the body’s own blood vessel walls. Platelets start clumping in tiny vessels. Red blood cells get sheared apart as they squeeze past clots in the microvasculature. The hallmark picture of TMA, with falling platelet counts, fragmented red cells, and rising markers of organ damage, takes shape from this vicious cycle of endothelial injury and unchecked complement activation.

The Role of the Alternative Complement Pathway

Research over the past decade has increasingly pointed to the alternative complement pathway as a central driver of HSCT-TMA. In patients who develop TMA, blood levels of Ba, a marker of alternative pathway activation, climb significantly from their pre-transplant baseline, and kidney tissue from affected patients shows heavy deposits of activated complement protein C3 along with shedding of thrombomodulin, a sign of endothelial distress.² A study in children with HSCT-TMA found a high rate of deletions in genes related to complement factor H, which normally restrains alternative pathway activity, along with autoantibodies against complement factor H in affected patients but not in transplant recipients who stayed TMA-free.³

Newer work has identified a previously unrecognized mechanism: the enzyme tissue kallikrein 1 (KLK1), when its normal inactivation is impaired, can cleave complement component C3 directly and kick the alternative pathway into overdrive. In mouse models challenged with cyclosporine and bacterial endotoxin, two known triggers of HSCT-TMA, researchers observed increased alternative pathway activation, kidney endothelial injury, and worsening kidney function in the setting of reduced KLK1 inactivation.² This represents a noncanonical route by which the alternative pathway can become activated, one that sits outside the classical cascade most clinicians learn about, and it may eventually open up new treatment targets.

Genetic Susceptibility and Why Some Patients Are Hit Harder

Not everyone who undergoes a stem cell transplant develops TMA, even when exposed to similar conditioning regimens and immunosuppressive drugs. Genetics appear to play a meaningful role in who is vulnerable. In a study of 77 transplant patients who underwent genetic testing, about two-thirds of those who developed TMA carried variants in at least one complement or coagulation gene, compared with only about nine percent of patients without TMA.⁴ The disparity was stark. Nonwhite patients with TMA carried more gene variants on average than white patients with TMA, and those with variants in three or more genes had particularly high mortality, around 71%.⁴

RNA analysis of pre-transplant blood samples showed that patients who later developed TMA and carried gene variants already had upregulated complement pathways before the transplant even began. This is a provocative finding because it suggests that genetic testing before transplant could, in theory, flag patients at higher risk. In clinical practice, however, routine pre-transplant complement gene panels are not yet standard, partly because the relationship between specific variants and disease severity is still being worked out. Even variants that computational tools predicted to be probably harmless were associated with upregulated complement activity in patients who went on to develop TMA, making it difficult to sort signal from noise using current predictive algorithms.

Why Diagnosis Remains So Difficult

One of the core frustrations with HSCT-TMA is that it shares its most visible features with a dozen other post-transplant complications. Falling platelet counts, rising creatinine, and anemia are practically universal in the early weeks after a stem cell transplant, making it hard to tell whether TMA is developing or whether the patient is simply going through the rough recovery that follows intensive conditioning. The classic hallmarks of TMA, such as fragmented red cells on a blood smear, are helpful when present but are not always found, especially early on. Kidney injury is often initially blamed on drug toxicity or infection. A case report described a patient whose worsening kidney function after transplant was initially attributed to a viral infection and antiviral drug toxicity; only after a kidney biopsy showed extensive complement staining was renal TMA identified.⁵

Compounding the problem, the transplant community has used different diagnostic criteria for years, and they do not capture the same patients. A prospective pediatric study compared the older criteria based on classic signs of microangiopathic hemolytic anemia (MAHA) with the newer definition proposed by the American Society for Transplantation and Cellular Therapy (ASTCT). The traditional criteria identified TMA in about 13% of patients by day 100 after transplant; the ASTCT high-risk definition doubled that to roughly 29%.⁶ The patients captured only by the newer, broader definition had benign complement biomarker profiles and 100% survival at day 100 without TMA-directed treatment, raising concerns that the more sensitive criteria risk overdiagnosis and overtreatment.⁶ An international expert panel from ASTCT, CIBMTR, EBMT, and APBMT has since convened to harmonize diagnostic and response criteria, though a fully unified standard is still emerging.⁷

Biomarkers That May Catch TMA Earlier

Because the clinical signs overlap with so many other post-transplant problems, researchers have been hunting for blood-based biomarkers that can flag TMA before it becomes clinically obvious. A prospective pediatric study measuring complement markers found that levels of sC5b-9, the terminal complement activation product, were already significantly higher in patients who later developed TMA than in matched controls, even before the transplant took place. By the early post-transplant period, Ba levels were also elevated in future TMA cases. At the time of TMA diagnosis, all three biomarkers examined, sC5b-9, Ba, and angiopoietin-2, were significantly higher in affected patients than in controls.⁸

The practical implication is tantalizing: if sC5b-9 is elevated before transplant, it could help identify patients who warrant closer surveillance. But these assays are not yet widely available in routine clinical labs, the study involved a small number of matched patients, and cutoff values that cleanly separate patients destined for TMA from those who will not develop it have not been firmly established. For now, biomarker testing is mostly confined to specialized centers and research protocols.

Organ Damage Beyond the Bloodstream

HSCT-TMA is sometimes described as a blood disorder, but the damage it causes extends well beyond red cells and platelets. The microangiopathic process can injure the small blood vessels of virtually any organ, and a systematic review found significant associations between TMA and a broad range of complications. In adults and children undergoing allogeneic transplant, TMA was linked to gastrointestinal bleeding, liver injury, neurological symptoms, pericardial effusions, and severe graft-versus-host disease. Infections were also strongly associated, with one adult allogeneic analysis showing more than a ninefold increase in odds.⁹

The kidneys bear much of the burden. A case series examining kidney biopsies from allogeneic transplant recipients with kidney injury found that TMA was the most common pathologic finding, present in 10 of the biopsied patients, though the biopsies also revealed a heterogeneous mix of other injuries including acute tubular damage and membranous nephropathy.¹⁰ Central nervous system involvement can manifest as seizures, encephalopathy, or posterior reversible encephalopathy syndrome, and intestinal vascular injury can produce ischemic colitis and bleeding that mimics GI graft-versus-host disease.¹¹

In children, prolonged TMA has been linked to pulmonary arterial hypertension, a dangerous complication in which the blood vessels of the lungs become damaged and narrowed. A series of five pediatric patients with sustained TMA who developed sudden hypoxemic respiratory failure and evidence of severe pulmonary hypertension ended with autopsies in three of four deceased patients showing pulmonary vascular disease consistent with TMA.¹² This is one of the most feared late manifestations and underscores that TMA is a systemic endothelial disease, not just a hematologic abnormality.

Treatment Options and Their Limitations

There is no universally agreed-upon frontline therapy for HSCT-TMA, and the treatment landscape is a patchwork of complement-targeted drugs, supportive measures, and older approaches that have not held up well. Therapeutic plasma exchange (TPE) was once a mainstay, borrowed from the treatment of other forms of TMA. But in HSCT-TMA specifically, TPE has been disappointing. A ten-year institutional review of 15 patients who completed courses of TPE lasting up to 25 weeks found that 14 developed chronic kidney disease, a third progressed to severe kidney disease, and six required dialysis. The authors concluded that TPE was ineffective at preventing kidney damage in this setting.¹³

Eculizumab, a monoclonal antibody that blocks the terminal complement protein C5, has become the most widely studied complement-targeted treatment for HSCT-TMA. A systematic review and meta-analysis found that eculizumab improved survival rates and overall response in patients with TMA and was generally well tolerated.¹⁴ However, the authors cautioned that the evidence base was limited, consisting mainly of observational data rather than randomized controlled trials. Dosing is complicated by the fact that transplant patients often have altered drug clearance, and the cost of eculizumab is substantial, which creates access barriers at many institutions.

Defibrotide, a drug approved in the US and Europe for treating another post-transplant vascular complication called veno-occlusive disease, has attracted interest for its broader endothelial protective properties. It works by stabilizing endothelial cells, restoring the balance between clotting and clot-dissolving activity, and reducing inflammation and oxidative stress at the vessel wall.¹⁵ While defibrotide is not approved specifically for TMA, its mechanism addresses the upstream endothelial injury that triggers the complement cascade, and some centers use it as part of a multi-pronged approach.

Newer Complement-Targeted Therapies

Narsoplimab represents a different strategy. Rather than blocking the terminal complement pathway like eculizumab does, it targets the lectin pathway of complement by inhibiting an enzyme called MASP-2. The rationale is that endothelial injury activates the lectin pathway specifically, so blocking it closer to the source may interrupt the process more precisely. In a clinical study of adults with HSCT-TMA, narsoplimab treatment improved laboratory TMA markers and was associated with clinical response and favorable overall survival.¹⁶ A real-world experience across pediatric and adult patients reported that about two-thirds responded, achieving transfusion independence and significant clinical improvement. Among responders, survival at 100 days after TMA diagnosis was 100%, and no increased rate of infectious complications was observed.¹⁷ Narsoplimab’s regulatory path has been complicated, however, and its availability remains limited.

Even more recently, iptacopan, a small-molecule inhibitor of complement factor B that targets the alternative pathway specifically, has shown promise in early case reports. Two adult patients with TMA after allogeneic transplant, one with early-onset and one with delayed-onset disease, experienced significant clinical and biochemical recovery after starting iptacopan.¹⁸ Two cases are not enough to draw broad conclusions, but a factor B inhibitor is conceptually appealing given the strong evidence implicating the alternative pathway in HSCT-TMA. Unlike eculizumab, which acts at the terminal end of the cascade and leaves upstream complement activity intact, iptacopan would shut down the alternative pathway at an earlier step, potentially offering a more targeted approach for patients whose disease is clearly alternative-pathway driven.

Long-Term Kidney and Survival Outcomes

Even when patients survive the acute phase of HSCT-TMA, the long-term consequences can be severe. In a large cohort analysis, both definite and probable TMA were independently associated with higher overall mortality, with definite TMA carrying a hazard ratio above 5 for both death and long-term kidney dysfunction compared with patients without TMA. The association held after adjusting for other risk factors and extended to non-relapse mortality and shorter progression-free survival.¹⁹

Chronic kidney disease is among the most common lasting consequences. A study of patients who received T cell-depleted transplants found a cumulative incidence of sustained chronic kidney disease approaching half of all patients who had received total body irradiation-based conditioning, with TMA, older age, and radiation exposure all identified as independent risk factors.²⁰ This is not a minor laboratory finding. Some of these patients end up on dialysis or require a kidney transplant. The TPE data cited earlier underscore the point: even prolonged courses of plasma exchange did not prevent the slide into chronic kidney disease, with dialysis needed in a substantial fraction.¹³

There is a real tension in clinical practice between the need for early, aggressive treatment to prevent irreversible organ damage and the risk of treating patients who would have done fine without intervention. The broader ASTCT criteria capture more patients earlier, which sounds like a good thing, but the prospective validation data suggest that a significant portion of those extra patients have mild disease with excellent outcomes regardless of whether they receive TMA-directed therapy. Conversely, waiting for the full picture of classic hemolytic TMA to develop before acting means that patients with organ-threatening disease may lose precious time. Getting this balance right is arguably the central clinical challenge in HSCT-TMA today, and it is one that better biomarkers, genetic risk stratification, and more refined diagnostic criteria are all trying to address simultaneously.

Distinguishing HSCT-TMA From Other Thrombotic Microangiopathies

HSCT-TMA is not the same disease as the better-known thrombotic microangiopathies that occur outside the transplant setting. Classic thrombotic thrombocytopenic purpura (TTP) is driven by a deficiency of the enzyme ADAMTS13, and hemolytic uremic syndrome in its typical form is triggered by Shiga toxin-producing bacteria. In HSCT-TMA, ADAMTS13 levels are usually normal or only mildly reduced, and the bacterial trigger is absent. The disease mechanism is fundamentally different: it starts with transplant-related endothelial injury that feeds into complement overactivation, particularly through the alternative pathway, rather than a single enzyme deficiency or toxin exposure.

This distinction matters practically because treatments designed for other TMAs do not reliably work in the transplant setting. Plasma exchange, which is effective in TTP because it replenishes the missing enzyme and removes autoantibodies against it, does not address the complement-driven endothelial damage that characterizes HSCT-TMA. Similarly, the clinical presentation differs: HSCT-TMA unfolds against a backdrop of immunosuppression, active infections, graft-versus-host disease, and multi-drug toxicity that can each independently produce findings that look like TMA. Clinicians managing transplant patients need to think of HSCT-TMA as its own entity with its own pathophysiology and its own treatment logic, rather than as a variant of TTP or atypical HUS that happens to occur after a transplant.

Graft-Versus-Host Disease and the Diagnostic Overlap

Severe acute graft-versus-host disease (GVHD) and HSCT-TMA frequently coexist, and separating the two can be genuinely agonizing for clinicians. Both can cause gastrointestinal bleeding, both can worsen kidney function, and both are associated with an inflamed, damaged endothelium. The systematic review of TMA-associated signs found that grade III-IV acute GVHD was significantly associated with HSCT-TMA.⁹ In some patients, the two conditions likely feed each other: GVHD drives inflammation and endothelial activation, which worsens complement-mediated TMA, which in turn damages the gut and other organs in ways that look like worsening GVHD.

The treatment implications are thorny. Calcineurin inhibitors used to treat GVHD are themselves implicated in triggering or worsening TMA. If a patient has both, intensifying immunosuppression to control GVHD may simultaneously aggravate TMA, while reducing calcineurin inhibitors to protect the endothelium may allow GVHD to flare. There is no clean solution, and management usually involves a careful, individualized balancing act: switching to alternative immunosuppressants when possible, adding complement-directed therapy, and monitoring closely for signs that either condition is gaining the upper hand. This overlap is one reason that experienced transplant centers tend to manage HSCT-TMA as a multidisciplinary problem involving hematologists, nephrologists, and transplant physicians rather than delegating it to any single specialty.